Correction to: "Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport."

The corresponding author of the above article [Kulkarni P, Korzekwa, K, Nagar, S (2016) *J Pharmacol Exp Ther* **359**:26-36. DOI: https://doi.org/10.1124/jpet.116.235689], Swati Nagar has recently identified an error.

In the modeling exercise, the CLo was inadvertently fixed in the Atv+ABT+RIF dataset, resulting in a value of fum = 0.54 instead of the experimentally obtained fum = 0.84. While literature values of fum of 0.56 have been reported (Watanabe et al, Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans, Drug Metabolism and Disposition, 2010, 38:215-222), the intent of this work was to use the experimentally obtained value of 0.84. This error resulted in an inaccurate estimation of CLae. The CLae estimate is increased by a factor of 20 (88, 82, and 70 ml/min instead of 4.4, 4.1 and 3.5 ml/min respectively, Table 1). Use of the correct fum and CLae estimates increases the predicted unbound intracellular concentration at 50 min for the Atv+ABT+RIF dataset (passive diffusion only) from 0.58 $\mu\rm M$ (Table 3) to 0.9 $\mu\rm M$.

The impact of active uptake on predicted unbound intracellular concentration is unchanged (0.9 and 8.14 μ M Atv+ABT+RIF and Atv+ABT respectively) compared to the previously Atv+ABT+published results (0.58 and 6.5 μ M RIF and Atv+ABT respectively, Table 3).

These corrections do not change the overall results and conclusions in the article.

The authors apologize for the error.